Evidence map›Paper›PMID 36929344›Full record

ArticleNeurology and therapy2023

A Randomized, Double-Blind, Placebo-Controlled, Parallel Study Investigating the Efficacy of a Whole Coffee Cherry Extract and Phosphatidylserine Formulation on Cognitive Performance of Healthy Adults with Self-Perceived Memory Problems.

Katarina M Doma, Erin D Lewis, Jane M Barracato, Lauren R Brink, Alejandra A Gratson, Neeraj Pandey, David C Crowley, Malkanthi Evans

Abstract read
In one paragraph

Article in Neurology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Immobilization of Phospholipase D on FeMolecules (Basel, Switzerland) · 2025
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katarina M DomaKGK Science Inc, 275 Dundas Street, Tower A Suite A1605, London, ON, N6B 3L1, Canada.
Erin D LewisKGK Science Inc, 275 Dundas Street, Tower A Suite A1605, London, ON, N6B 3L1, Canada. elewis@kgkscience.com.ORCID http://orcid.org/0000-0002-1760-3073
Jane M BarracatoGlobal Medical Science, Reckitt, 399 Interpace Parkway, P.O. Box 225, Parsippany, NJ, 07054-0225, USA.
Lauren R BrinkGlobal Medical Science, Reckitt, 399 Interpace Parkway, P.O. Box 225, Parsippany, NJ, 07054-0225, USA.
Alejandra A GratsonGlobal Medical Science, Reckitt, 399 Interpace Parkway, P.O. Box 225, Parsippany, NJ, 07054-0225, USA.
Neeraj PandeyMedical and Scientific Affairs, Reckitt, Turner House 103-105 Bath Road, Slough, Berkshire, SL1 3UH, UK.
David C CrowleyKGK Science Inc, 275 Dundas Street, Tower A Suite A1605, London, ON, N6B 3L1, Canada.
Malkanthi EvansKGK Science Inc, 275 Dundas Street, Tower A Suite A1605, London, ON, N6B 3L1, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCognition refers to brain functions including memory, learning, and thought processing and is increasingly important to individuals. However, impairment of cognitive function is a concern among North American adults. Therefore, effective and reliable treatments are needed.

methodsThis randomized, double-blind, placebo-controlled study examined the effects of 42 days of Neuriva® supplementation, a whole coffee cherry extract and phosphatidylserine supplement, on memory, accuracy, focus and concentration and learning among 138 healthy adults (40-65 years) with self-reported memory problems. Plasma brain-derived neurotrophic factor (BDNF) levels, Computerized Mental Performance Assessment System (COMPASS) tasks, the Everyday Memory Questionnaire (EMQ), and Go/No-Go tests were assessed at baseline and day 42.

resultsAs compared to placebo, Neuriva® supplementation elicited greater improvements at day 42 in numeric working memory COMPASS task accuracy outcomes (p ≤ 0.024) which assessed memory, accuracy, and focus and concentration, and reaction time outcomes (p ≤ 0.031) which assessed memory as well as focus and concentration. Neuriva® supplementation improved overall accuracy (p = 0.035) in the picture recognition task that assessed memory, accuracy, and learning compared to placebo. No significant differences between groups were observed for BDNF, the EMQ, or Go/No-Go tests.

conclusionResults suggest 42 days of Neuriva® supplementation was safe, well tolerated, and beneficial in improving memory, accuracy, focus and concentration, and learning in a healthy adult population with self-reported memory problems.

Indexed as

CognitionDietary supplementMemoryNutraceutical

Identifiers

PMID36929344
PMCPMC10195946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.